Abstract

Introduction. The population-level survival analysis for cancer patients was not carried out in Russia due to the absence of population-based cancer registries, meeting the requirements of international Agency for Research on Cancer. This opportunity has appeared only with the establishment of the population-based cancer registry in St. Petersburg. Cancer survival estimation is possible only under conditions of strict adherence to the principles of the study. Analysis of survival of cancer patients is the main criterion of the objective assessment of the effectiveness of anticancer therapy. Malignant tumors of the nasal cavity, middle ear and accessory sinuses are classified by two ICD-10 diagnosis codes: С30 and С31 (С30: malignant tumors of the nasal cavity and middle ear; C31: malignant tumors of accessory sinuses). Database of the population-based cancer registry promotes the study of survival by any parameter including the fourth character of the ICD-10 code and histological type of the tumor. Purposes and objectives. To estimate the observed and relative survival rates in patients with malignant tumors of the nasal cavity, middle ear and accessory sinuses and to compare the results obtained with the EU average (according to the EuroCare program), as well as to estimate survival of this group of patients according to sex, age, stage of disease and histological type of the tumor. Material and methods. Between 1994 and 2009, 565 cases with malignant tumors of the nasal cavity, middle ear and accessory sinuses were selected from the population-based cancer registry. There were used the observed and relative survival rates calculated according to the international standards. Results. We estimated the 5-year observed and relative survival rates in patients with cancers of the nasal cavity, middle ear and sinuses, using ICD-10 codes С30 and 31 and taking into account sex, age, stage of disease and histological structure of tumors. A clear trend toward increase in the 5-year observed and relative survival rates in patients with malignant tumors of the nasal cavity, middle ear and accessory sinuses was observed.

Highlights

  • The population-level survival analysis for cancer patients was not carried out in Russia due to the absence of population-based cancer registries, meeting the requirements of international Agency for Research on Cancer

  • Analysis of survival of cancer patients is the main criterion of the objective assessment of the effectiveness of anticancer therapy

  • Malignant tumors of the nasal cavity, middle ear and accessory sinuses are classified by two ICD-10 diagnosis codes: С30 and С31 (С30: malignant tumors of the nasal cavity and middle ear; C31: malignant tumors of accessory sinuses)

Read more

Summary

ЭПИДЕМИОЛОГИЧЕСКИЕ ИССЛЕДОВАНИЯ

ЭПИДЕМИОЛОГИЯ И ВЫЖИВАЕМОСТЬ БОЛЬНЫХ ЗЛОКАЧЕСТВЕННЫМИ НОВООБРАЗОВАНИЯМИ ПОЛОСТИ НОСА, СРЕДНЕГО УХА И ПРИДАТОЧНЫХ ПАЗУХ С УЧЕТОМ СТАДИИ ЗАБОЛЕВАНИЯ И ГИСТОЛОГИЧЕСКОЙ СТРУКТУРЫ. Для проведения исследования из БД ПРР отобрано 565 случаев ЗНО полости носа, среднего уха и придаточных пазух среди мужского и женского населения г. Наивысший стандартизованный показатель заболеваемости женщин ЗНО полости рта, среднего уха и придаточных пазух в 2014 г. Санкт-Петербурге регистрируется 10–20 новых случаев ЗНО полости носа, среднего уха и придаточных пазух среди мужского населения и 9–15 – среди женского [9, 12, 14, 15] Анализ динамики смертности населения от ЗНО полости носа, среднего уха и придаточных пазух провести невозможно, так как в государственной отчетности предусмотрена строка, характеризующая число умерших больных от данной причины совместно с рубриками С37,38 и 39.

Период наблюдения
Оба пола
Европейские страны
Морфологический тип
Наблюдаемая выживаемость
Сведения об авторах
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call